New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain
Identifieur interne : 000225 ( PascalFrancis/Checkpoint ); précédent : 000224; suivant : 000226New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain
Auteurs : Gregory A. Poland [États-Unis] ; Douglas M. Fleming [Royaume-Uni] ; John J. Treanor [États-Unis] ; Eugene Maraskovsky [Australie] ; Thomas C. Luke [États-Unis] ; Emma M. A. Ball [Australie] ; Caroline M. Poland [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2013.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX> adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.
Affiliations:
- Australie, Royaume-Uni, États-Unis
- Angleterre, Indiana, Maryland, Midlands de l'Ouest, Minnesota, Victoria (État), État de New York
- Birmingham, Melbourne
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:13-0212905Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain</title><author><name sortKey="Poland, Gregory A" sort="Poland, Gregory A" uniqKey="Poland G" first="Gregory A." last="Poland">Gregory A. Poland</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Mayo Clinic Vaccine Research Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Program in Translational Immunovirology and Biodefense, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Fleming, Douglas M" sort="Fleming, Douglas M" uniqKey="Fleming D" first="Douglas M." last="Fleming">Douglas M. Fleming</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>RCGP Research and Surveillance Centre</s1><s2>Birmingham</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J." last="Treanor">John J. Treanor</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Infectious Diseases, University of Rochester</s1><s2>Rochester, NY</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CSL Limited</s1><s2>Parkville</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>CSL Limited</wicri:noRegion></affiliation></author><author><name sortKey="Luke, Thomas C" sort="Luke, Thomas C" uniqKey="Luke T" first="Thomas C." last="Luke">Thomas C. Luke</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>The Henry Jackson Foundation, Naval Medical Research Center</s1><s2>Silver Spring, MD</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ball, Emma M A" sort="Ball, Emma M A" uniqKey="Ball E" first="Emma M. A." last="Ball">Emma M. A. Ball</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>BioCSL</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Poland, Caroline M" sort="Poland, Caroline M" uniqKey="Poland C" first="Caroline M." last="Poland">Caroline M. Poland</name><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Mental Health Counseling Center, Taylor University</s1><s2>Upland, IN</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0212905</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0212905 INIST</idno><idno type="RBID">Pascal:13-0212905</idno><idno type="wicri:Area/PascalFrancis/Corpus">000275</idno><idno type="wicri:Area/PascalFrancis/Curation">001B52</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000225</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000225</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain</title><author><name sortKey="Poland, Gregory A" sort="Poland, Gregory A" uniqKey="Poland G" first="Gregory A." last="Poland">Gregory A. Poland</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Mayo Clinic Vaccine Research Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Program in Translational Immunovirology and Biodefense, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Fleming, Douglas M" sort="Fleming, Douglas M" uniqKey="Fleming D" first="Douglas M." last="Fleming">Douglas M. Fleming</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>RCGP Research and Surveillance Centre</s1><s2>Birmingham</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J." last="Treanor">John J. Treanor</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Infectious Diseases, University of Rochester</s1><s2>Rochester, NY</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>CSL Limited</s1><s2>Parkville</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>CSL Limited</wicri:noRegion></affiliation></author><author><name sortKey="Luke, Thomas C" sort="Luke, Thomas C" uniqKey="Luke T" first="Thomas C." last="Luke">Thomas C. Luke</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>The Henry Jackson Foundation, Naval Medical Research Center</s1><s2>Silver Spring, MD</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ball, Emma M A" sort="Ball, Emma M A" uniqKey="Ball E" first="Emma M. A." last="Ball">Emma M. A. Ball</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>BioCSL</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Poland, Caroline M" sort="Poland, Caroline M" uniqKey="Poland C" first="Caroline M." last="Poland">Caroline M. Poland</name><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Mental Health Counseling Center, Taylor University</s1><s2>Upland, IN</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Congress</term><term>Immunological adjuvant</term><term>Immunotherapy</term><term>Influenza</term><term>Spain</term><term>Vaccine</term><term>World</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Vaccin</term><term>Monde</term><term>Congrès</term><term>Espagne</term><term>Immunothérapie</term><term>Adjuvant immunologique</term><term>Grippe</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX<sup></sup> > adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0></fA01><fA02 i1="01"><s0>VACCDE</s0></fA02><fA03 i2="1"><s0>Vaccine</s0></fA03><fA05><s2>31</s2></fA05><fA06><s3>SUP1</s3></fA06><fA08 i1="01" i2="1" l="ENG"><s1>New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Summary from a Scientific Symposium at the 4th Influenza Vaccines for the World (IVW), 2012 Congress, 11 October 2012, Valencia, Spain</s1></fA09><fA11 i1="01" i2="1"><s1>POLAND (Gregory A.)</s1></fA11><fA11 i1="02" i2="1"><s1>FLEMING (Douglas M.)</s1></fA11><fA11 i1="03" i2="1"><s1>TREANOR (John J.)</s1></fA11><fA11 i1="04" i2="1"><s1>MARASKOVSKY (Eugene)</s1></fA11><fA11 i1="05" i2="1"><s1>LUKE (Thomas C.)</s1></fA11><fA11 i1="06" i2="1"><s1>BALL (Emma M. A.)</s1></fA11><fA11 i1="07" i2="1"><s1>POLAND (Caroline M.)</s1></fA11><fA12 i1="01" i2="1"><s1>BABIUK (Lorne)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>Mayo Clinic Vaccine Research Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Program in Translational Immunovirology and Biodefense, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>RCGP Research and Surveillance Centre</s1><s2>Birmingham</s2><s3>GBR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Division of Infectious Diseases, University of Rochester</s1><s2>Rochester, NY</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>CSL Limited</s1><s2>Parkville</s2><s3>AUS</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>The Henry Jackson Foundation, Naval Medical Research Center</s1><s2>Silver Spring, MD</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>BioCSL</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>6 aut.</sZ></fA14><fA14 i1="08"><s1>Mental Health Counseling Center, Taylor University</s1><s2>Upland, IN</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA15 i1="01"><s1>University of Alberta</s1><s3>CAN</s3><sZ>1 aut.</sZ></fA15><fA20><s2>A1-A20</s2></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289</s2><s5>354000504179980010</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>125 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>13-0212905</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX<sup></sup> > adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Vaccin</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Vaccine</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Vacuna</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Monde</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>World</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Mundo</s0><s2>NG</s2><s5>06</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Congrès</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Congress</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Congreso</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Espagne</s0><s2>NG</s2><s5>08</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Spain</s0><s2>NG</s2><s5>08</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>España</s0><s2>NG</s2><s5>08</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Immunothérapie</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Immunotherapy</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Inmunoterapia</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Adjuvant immunologique</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Immunological adjuvant</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Grippe</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Influenza</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Gripe</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Europe Sud</s0><s2>NG</s2><s5>13</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Southern Europe</s0><s2>NG</s2><s5>13</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Europa Sur</s0><s2>NG</s2><s5>13</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Infección</s0></fC07><fN21><s1>196</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Indiana</li><li>Maryland</li><li>Midlands de l'Ouest</li><li>Minnesota</li><li>Victoria (État)</li><li>État de New York</li></region><settlement><li>Birmingham</li><li>Melbourne</li></settlement></list><tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Poland, Gregory A" sort="Poland, Gregory A" uniqKey="Poland G" first="Gregory A." last="Poland">Gregory A. Poland</name></region><name sortKey="Luke, Thomas C" sort="Luke, Thomas C" uniqKey="Luke T" first="Thomas C." last="Luke">Thomas C. Luke</name><name sortKey="Poland, Caroline M" sort="Poland, Caroline M" uniqKey="Poland C" first="Caroline M." last="Poland">Caroline M. Poland</name><name sortKey="Poland, Gregory A" sort="Poland, Gregory A" uniqKey="Poland G" first="Gregory A." last="Poland">Gregory A. Poland</name><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J." last="Treanor">John J. Treanor</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Fleming, Douglas M" sort="Fleming, Douglas M" uniqKey="Fleming D" first="Douglas M." last="Fleming">Douglas M. Fleming</name></region></country><country name="Australie"><noRegion><name sortKey="Maraskovsky, Eugene" sort="Maraskovsky, Eugene" uniqKey="Maraskovsky E" first="Eugene" last="Maraskovsky">Eugene Maraskovsky</name></noRegion><name sortKey="Ball, Emma M A" sort="Ball, Emma M A" uniqKey="Ball E" first="Emma M. A." last="Ball">Emma M. A. Ball</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000225 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000225 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:13-0212905
|texte= New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain
}}
| This area was generated with Dilib version V0.6.34. |  |